The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

Intra-Cellular submitted its application to the FDA for Caplyta’s approval in major depressive disorder, potentially opening ...

Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...

The collaboration will see COUR and Roche’s Genentech leverage the biotech’s antigen-specific immune tolerance platform to ...

At Drexel University’s Graduate School of Biomedical Sciences and Professional Studies, graduate students and active ...

Alongside the layoffs, Alligator will also suspend work on all of its earlier-stage assets and devote its resources to lead ...

The FDA last week announced that it is looking into the safety of bluebird bio ’s gene therapy Skysona (elivaldogene ...

After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ ...

At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus ...

Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...

Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics ...